LOS ANGELES CAPITAL MANAGEMENT LLC

Position in KRYS — Krystal Biotech, Inc.

CIK 1177206 LOS ANGELES, CA

Position in KRYS

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$43,857

-$516,955 QoQ

Shares Held

118

-94.6% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#342

of 419 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. KRYS ranks #116 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$43,857	118	-94.6%	Shares	Sole	2026-08-13
2026-03-31	$560,812	2,171	0.0%	Shares	Sole	2026-05-08
2025-12-31	$535,238	2,171	-67.9%	Shares	Sole	2026-02-11
2025-09-30	$1,192,813	6,757	-74.6%	Shares	Sole	2025-10-20
2025-06-30	$3,661,659	26,638	+6.9%	Shares	Sole	2025-08-07
2025-03-31	$4,494,698	24,929	+152.2%	Shares	Sole	2025-05-05
2024-12-31	$1,548,427	9,884	0.0%	Shares	Sole	2025-02-04
2024-09-30	$1,799,184	9,884	-1.0%	Shares	Sole	2024-11-04
2024-06-30	$1,833,461	9,984	-2.3%	Shares	Sole	2024-08-05
2024-03-31	$1,817,377	10,214	+6.6%	Shares	Sole	2024-04-05
2023-12-31	$1,189,115	9,585	-5.3%	Shares	Sole	2024-02-06
2023-09-30	$1,174,268	10,123	-36.6%	Shares	Sole	2023-11-06
2023-06-30	$1,873,938	15,962	—	Shares	Sole	2023-08-03
No filing history on record for this holder in this stock.